Age and severe adverse drug reactions caused by nifedipine and verapamil

Journal of Clinical Epidemiology

Volumn 49, Issue 8, 1996, Pages 921-928

  Pahor, Marco ^a,c   Manto, Andrea ^a   Pedone, Claudio ^a   Carosella, Luciana ^a   Guralnik, Jack M ^b   Carbonin, Pierugo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b NATIONAL INSTITUTE ON AGING   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Adverse drug reactions; Age; Calcium antagonists; Comorbidity; Nifedipine; Verapamil

Indexed keywords

AMLODIPINE; CALCIUM ANTAGONIST; DILTIAZEM; NICARDIPINE; NIFEDIPINE; NIMODIPINE; VERAPAMIL;

ACUTE KIDNEY FAILURE; ADULT; AGE; AGED; ARTICLE; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; DRUG SURVEILLANCE PROGRAM; FEMALE; GENDER; HOSPITALIZATION; HUMAN; HYPOTENSION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; RISK; TACHYCARDIA;

EID: 0030220702     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/0895-4356(96)00056-X     Document Type: Article

References (42)

1. 1. Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1326-1331.
2. 2. Psaty BM, Heckbert SR, Koepsell TD et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274: 654-655.
3. 3. Pahor M, Guralnik JM, Corti C, Foley DJ, Carbonin PU, Havlik RJ. Long-term survival and use of antihypertensive medications in older persons. J Am Geriatr Soc 1995; 43: 1191-1197.
4. 4. Packer M. Combined beta-adrenergic and calcium-entry blockade in angina pectoris. N Engl J Med 1989; 320: 709-718.
5. 5. Subramanian VB, Paramasivan R, Lahiri A, Raftery EB. Verapamil in chronic stable angina. A controlled study with computerised multistage treadmill exercise. Lancet 1980; April 19: 841-844.
6. 6. Crea F, Deanfield J, Crean P, Sharom M, Davies G, Maseri A. Effects of verapamil in preventing early postinfarction angina and reinfarction. Am J Cardiol 1985; 55: 900-904.
7. 7. Johnson SM, Mauritson DR, Willerson JT, Hillis LD. A controlled trial of verapamil for prinzmetal's variant angina. N Engl J Med 1981; 304: 862-866.
8. 8. The Israeli Sprint Study Group. Secondary prevention reinfarction Israeli nifedipine trial (SPRINT). A randomized intervention trial of nifedipine in patients with acute mycardial infarction. The Israel Sprint Study Group. Eur Heart J 1988; 9: 354-364.
9. 9. Lichtlen PR, Hugenholtz PG, Rafflenbeul W, Hecker H, Jost S, Deckers JW. Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifidipine Trial on Antiatherosclerotic Therapy (INTACT). INTACT Group Investigators. Lancet 1990; 335: 1109-1113.
10. 10. The Danish Study Group on Verapamil in Myocardial Infarction. Effect of verapamil on mortality and major events after acute myocardial infarction (The Danish Verapamil Infarction Trial II - DAVIT II). Am J Cardiol 1990; 66: 779-785.
11. 11. Muller JE, Morrison J, Stone PH et al. Nifedipine therapy for patients with threatened and acute myocardial infarction: A randomized, double blind, placebo-controlled comparison. Circulation 1984; 69: 740-747.
12. 12. Parodi O, Maseri A, Simonetti I. Management of unstable angina at rest by verapamil. A double-blind cross-over study in coronary care unit. Br Heart J 1979; 41; 167-174.
13. 13. Wilcox RG, Hampton JR, Banks DC et al.. Trial of nifedipine in acute myocardial infarction: The Trent study. Br Med J 1986; 293: 1204-1208.
14. 14. Rengo F, Carbonin PU, Pahor M et al.. A controlled trial of verapamil in post-myocardial infarction. Results of the Calcium-Antagonist Reinfarction Italian Study - CRIS. Am J Cardiol 1996; 77: 365-369.
15. 15. Pahor M, Guralnik JM, Gambassi G Jr, Bernabei R, Carosella L, Carbonin PU. The impact of age on the risk of adverse drug reactions to digoxin. J Clin Epidemiol 1993; 46: 1305-1314.
16. 16. Pahor M, Bernabei R, Carosella L, Gambassi G Jr, Manto A, Carbonin PU. Mental status can bias detection of adverse drug reactions in hospitalized patients. Facts Res Gerontol 1993; 7: 271-275.
17. 17. Carbonin PU, Pahor M, Bernabei R, Sgadari A: Is age an independent risk factor of adverse drug reactions in hospitalized medical patients? J Am Geriatr Soc 1991; 39: 1093-1099.
18. 18. Pahor M, Mugelli A, Guralnik JM et al. Age and laxative use in hospitalized patients. A report of the Gruppo Italiano di Farmacovigilanza nell'Anziano (GIFA). Aging (Milano) 1995; 7: 128-135.
19. 19. Pahor M, Chrischilles EA, Guralnik JM, Brown SL, Wallace RB, Carbonin PU. Drug data coding and analysis in epidemiologic studies. Eur J Epidemiol 1994; 10: 405-411.
20. 20. PHS-HCF. International Classification of Diseases, 9th rev. Clinical Modification. Public Health Service-Health Care Financing Administration, Washington, D.C. 1980.
21. 21. Charlson ME, Pompei P, Ales KL, Mackenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chron Dis 1987; 40: 373-383.
22. 22. Deyo RA, Gherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45: 613-619.
23. 23. Naranjo CA, Busto U, Sellers EM et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-245.
24. 24. Sirnes PA, Overskeid K, Pedersen TR et al. Evolution of infarct size during the early use of nifedipine in patients with acute myocardial infarction: The Norwegian Nifedipine Multicenter Trial. Circulation 1984; 70: 638-644.
25. 25. Hosie J, Hosie G, Meredith PA. The effects of age on the pharmacodynamics and pharmacokinetics of two formulations of verapamil. J Cardiovasc Pharmacol 1989; 13(Suppl. 4): S60-S62.
26. 26. Abernethy DR, Wainer IW, Longstreth JA, Andrawis NS. Stereoselective verapamil disposition and dynamics in aging during racemic verapamil administration. J Pharmacol Exp Ther 1993; 266: 904-911.
27. 27. Robertson DR, Waller DG, Renwick AG, George CF. Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine. Br J Clin Pharmacol 1988; 25: 297-305.
28. 28. Scott M, Castleden CM, Adam HK, Smith RP, Fitzsimons TJ. The effect of ageing on the disposition of nifedipine and atenolol. Br J Clin Pharmacol 1988; 25: 289-296.
29. 29. Schwartz JB. Aging alters verapamil elimination and dynamics: Single dose and steady-state responses. J Pharmacol Exp Ther 1990; 255: 364-373.
30. 30. Schwartz JB, Troconiz IF, Verotta D, Liu S, Capili H. Aging effects on stereoselective pharmacokinetics and pharmacodynamics of verapamil. J Pharmacol Exp Ther 1993; 265: 690-698.
31. 31. Schwartz JB, Capili H, Daugherty J. Aging of women alters S-verapamil pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 1994; 55: 509-517.
32. 32. Schwartz JB. The effects of aging on responses to verapamil in isolated right atria. J Gerontol 1989; 44: M201-M205.
33. 33. Carosella L, Menichelli P, Alimenti M et al. Verapamil disposition and cardiovascular effects in elderly patients after single intravenous and oral doses. Cardiovasc Drugs Ther 1989; 3: 417-425.
34. 34. Carter BL, Noyes MA, Demmler RW. Differences in serum concentrations of and responses to generic verapamil in the elderly. Pharmacotherapy 1993; 13: 359-368.
35. 35. Ahmed JH, Meredith PA, Elliott HL. The influence of age on the pharmacokinetics of verapamil. Pharmacol Res 1991; 24: 227-233.
36. 36. Ahmed JH, Elliott HL, Meredith PA, Reid JL. Low-dose verapamil in middle-aged and elderly patients with angina pectoris: No evidence of increased susceptibility to the cardiac effects. Cardiovasc Drugs Ther 1992; 6: 153-158.
37. 37. Sasaki M, Tateishi T, Ebihara A. The effects of age and gender on the stereoselective pharmacokinetics of verapamil. Clin Pharmacol Ther 1993; 54: 278-285.
38. 38. Frishman WH, Kirsten E, Klein M et al. Clinical relevance of verapamil plasma levels in stable angina pectoris. Am J Cardiol 1982; 50: 1080-1084.
39. 39. Pahor M, Cecchi E, Fumagalli S, et al. Association of serum creatinine and age with headache caused by nitrates. Clin Pharmacol Ther 1995; 58: 470-481.
40. 40. Pahor M, Guralnik JM, Chrischilles EA, Wallace RB. Use of laxative medication in older persons and associations with low serum albumin. J Am Geriatr 1994; 42: 50-56.
41. 41. Pahor M, Guralnik JM, Salive ME, Chrischilles EA, Wallace RB. Disability and severe gastrointestinal hemorrhage. A prospective study of community dwelling older persons. J Am Geriatr Soc 1994; 42: 816-825.
42. 42. Brown SL, Salive ME, Pahor M et al. Occult caffeine as a source of sleep problems in an older population. J Am Geriatr Soc 1995; 43: 860-864.